Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 8% - What's Next?

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report)'s share price rose 8% during trading on Monday . The stock traded as high as $10.25 and last traded at $10.49. Approximately 50,125 shares changed hands during mid-day trading, a decline of 92% from the average daily volume of 591,811 shares. The stock had previously closed at $9.71.

Wall Street Analyst Weigh In

BCAX has been the subject of several analyst reports. Wells Fargo & Company upgraded Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 target price for the company in a research note on Friday, May 23rd. Wedbush restated an "outperform" rating and set a $30.00 price target on shares of Bicara Therapeutics in a research note on Friday, May 23rd. Wall Street Zen lowered Bicara Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Stifel Nicolaus set a $48.00 price target on Bicara Therapeutics in a research note on Thursday, March 27th. Finally, HC Wainwright dropped their price target on Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating for the company in a research note on Friday, May 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Bicara Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $31.86.

Bicara Therapeutics Stock Up 8.0%

The business has a 50 day moving average price of $10.88 and a 200-day moving average price of $12.38.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.28). Analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Institutional Investors Weigh In On Bicara Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Atle Fund Management AB grew its stake in Bicara Therapeutics by 23.0% during the 2nd quarter. Atle Fund Management AB now owns 147,380 shares of the company's stock valued at $1,369,000 after purchasing an additional 27,547 shares in the last quarter. Rhumbline Advisers grew its stake in Bicara Therapeutics by 21.1% during the 1st quarter. Rhumbline Advisers now owns 23,018 shares of the company's stock valued at $300,000 after purchasing an additional 4,010 shares in the last quarter. Woodline Partners LP grew its stake in Bicara Therapeutics by 26.5% during the 1st quarter. Woodline Partners LP now owns 348,690 shares of the company's stock valued at $4,543,000 after purchasing an additional 72,998 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Bicara Therapeutics during the 1st quarter valued at approximately $248,000. Finally, Vestal Point Capital LP grew its stake in Bicara Therapeutics by 290.0% during the 1st quarter. Vestal Point Capital LP now owns 2,768,975 shares of the company's stock valued at $36,080,000 after purchasing an additional 2,058,975 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.